Jin Wang

The paper compares five quantitative proteomic methods to identify high-confidence longevity regulators in C. elegans by analyzing IIS mutants.

This paper identifies a novel non-canonical RT-loop degron in VAV1 and demonstrates how conformational restriction and computational modeling enhance molecular glue potency for proteasomal degradation.

This study develops LD5095, a novel cereblon-recruiting RIPK1 degrader, showing potent RIPK1 degradation and tumor sensitization to immune checkpoint inhibitors.

This study shows that reducing AQP4 function in a prion-CAA mouse model prolongs survival and reduces neuroinflammation without affecting prion spread.

This study shows that Hrs, an ESCRT-0 protein, modulates AMPA receptor currents and Ca2+-dependent signaling by sensing and responding to neuronal activity at synapses.

This paper introduces a method to reversibly regulate CYP1A2 enzyme activity in mice using a dTAG knock-in strategy, demonstrating its utility in drug metabolism studies.

The paper develops RSPO2-based peptibody-drug conjugates that target LGR4/5/6 receptors, showing potent anti-tumor activity in colorectal cancer and neuroblastoma models.

This paper develops and characterizes PSIRC3, a covalent PROTAC for BTK, showing it achieves potent degradation with sub-nanomolar potency and high selectivity, challenging the necessity of catalytic turnover for PROTAC efficacy.

This study designs and evaluates a novel RIPK1 degrader, LD5097, showing potent degradation activity, favorable pharmacokinetics, and enhanced antitumor effects in cancer models.

The paper develops an ultra-high-throughput LC-MS method for TPD compound screening, demonstrating high proteome coverage and quantitation accuracy.

COOKIE-Pro quantifies covalent inhibitor binding kinetics across the proteome, revealing off-targets and kinetic parameters for BTK inhibitors.

This paper evaluates two fluorescent tracers for use in TR-FRET and NanoBRET assays, showing they can be used across platforms with consistent performance.

This study evaluates AlphaFold3's performance in drug discovery tasks, finding it excels at static protein-ligand interactions but struggles with conformational changes, GPCR bias, and affinity ranking.

The paper challenges the validation of ZYS-1 as an ADAR1 inhibitor, showing it lacks inhibitory activity in validated assays.

This paper develops a first-in-class RIPK1 degrader, LD4172, which enhances antitumor immunity by promoting immunogenic cell death and sensitizing tumors to anti-PD1 therapy.

This paper develops a competition assay using homogenous TR-FRET to rank the affinities of high-affinity monoclonal antibodies and antibody-drug conjugates for a common antigen, enabling scalable and low-cost evaluation.

This study introduces lysineless HiBiT-RR and nLucK0 tagging systems to reduce degradation artifacts in monitoring protein degradation, showing HiBiT-RR retains sensitivity and nLucK0 shows different degradation patterns than nLucWT.

This study shows that low-dose cephaloridine induces colanic acid production in gut bacteria, extending host lifespan in C. elegans and mice.